Search

Your search keyword '"Ezhov, M."' showing total 335 results

Search Constraints

Start Over You searched for: Author "Ezhov, M." Remove constraint Author: "Ezhov, M."
335 results on '"Ezhov, M."'

Search Results

159. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

160. The Role of Nutraceuticals in Statin Intolerant Patients

161. Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

162. Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

163. Evolocumab and clinical outcomes in patients with cardiovascular disease

164. The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial.

165. [A clinical case of reverse left ventricular remodeling in patient with pathogenic TTN mutation. Case report].

166. Blood pressure measurement and assessment of arterial structure and function: an expert group position paper.

167. Validation of artificial intelligence application for dental caries diagnosis on intraoral bitewing and periapical radiographs.

168. Evaluation of a Decision Support System Developed with Deep Learning Approach for Detecting Dental Caries with Cone-Beam Computed Tomography Imaging.

169. [Association of cardiovascular disease with hospital mortality in COVID-19 patients].

170. Assessing the reliability of CBCT-based AI-generated STL files in diagnosing osseous changes of the mandibular condyle: a comparative study with ground truth diagnosis.

171. Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook.

172. Determining the reliability of diagnosis and treatment using artificial intelligence software with panoramic radiographs.

173. World Heart Federation Cholesterol Roadmap 2022.

174. AI-based automatic segmentation of craniomaxillofacial anatomy from CBCT scans for automatic detection of pharyngeal airway evaluations in OSA patients.

175. [The relationship between the level of Lр(а) and the prevalence of atherosclerosis among young patients].

177. Evaluation of artificial intelligence for detecting impacted third molars on cone-beam computed tomography scans.

178. Clinically applicable artificial intelligence system for dental diagnosis with CBCT.

179. A deep learning approach for dental implant planning in cone-beam computed tomography images.

180. Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients.

181. Lipoprotein(a) Lowering-From Lipoprotein Apheresis to Antisense Oligonucleotide Approach.

182. [Optimization of lipid-lowering therapy in patients after ischemic stroke. Resolution of the Council of Experts].

183. The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale.

184. The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion.

185. Matrix Metalloproteinase 9 as a Predictor of Coronary Atherosclerotic Plaque Instability in Stable Coronary Heart Disease Patients with Elevated Lipoprotein(a) Levels.

186. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).

187. The association of lipoprotein(a) and apolipoprotein(a) phenotypes with peripheral artery disease.

188. The Role of Nutraceuticals in Statin Intolerant Patients.

189. [The Role of Lipoprotein(a) in the Development of Peripheral and Carotid Atherosclerosis].

190. Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity.

191. Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel.

192. Automatic identification of variables in epidemiological datasets using logic regression.

193. Normative values for carotid intima media thickness and its progression: Are they transferrable outside of their cohort of origin?

194. [Elevated Lipoprotein(a) Cncentration and Presence of Subfractions of Small Dense Low Density Lipoproteins as Independent Factors of Risk of Ischemic Heart Disease].

195. [Degenerative Aortic Stenosis: Modern View on Development, Course, and Management].

196. Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels.

197. Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype.

198. [Evolution of Lipoprotein(a): From Biomarker to the Therapeutic Target].

199. [The Evolution of Views on Lipoprotein(a): From Biomarker to the Therapeutic Target].

200. [Transcatheter Treatment of Degenerative Critical Aortic Valve Stenosis in a Patient With Severe Heart Failure and Chronic Lymphocytic Leukemia].

Catalog

Books, media, physical & digital resources